Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -26.20% is 55% above its 5-year average of -58.19%, near the high end of its 5-year range (-110.07%–-16.52%).
As of the fiscal period ended Tuesday, June 30, 2026. 58.05% above its 12-month average of -62.45%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -26.20%.
RETURN ON INVESTED CAPITAL (ROIC)
-26.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-62.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-73.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-58.19%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+58.05%
CURRENT VS 3Y AVG
+64.56%
CURRENT VS 5Y AVG
+54.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+26.53%
vs the sector median at left
Shattuck Labs, Inc.
Market Cap
$529.58M
Return on Invested Capital (ROIC)
-26.20%
TTM Avg
-62.45%
3Y Avg
-73.92%
5Y Avg
-58.19%
Market Cap
$531.52M
Return on Invested Capital (ROIC)
-317.86%
TTM Avg
-177.04%
3Y Avg
-169.25%
5Y Avg
-196.25%
Market Cap
$531.98M
Return on Invested Capital (ROIC)
-0.81%
TTM Avg
-8.59%
3Y Avg
-110.96%
5Y Avg
-102.03%
Market Cap
$533.04M
Return on Invested Capital (ROIC)
-16.89%
TTM Avg
-20.74%
3Y Avg
-75.97%
5Y Avg
-65.59%
Market Cap
$524.43M
Return on Invested Capital (ROIC)
-18.20%
TTM Avg
-95.31%
3Y Avg
-87.63%
5Y Avg
-71.60%
Market Cap
$538.01M
Return on Invested Capital (ROIC)
-78.31%
TTM Avg
-49.75%
3Y Avg
-41.99%
5Y Avg
-101.04%
Market Cap
$519.25M
Return on Invested Capital (ROIC)
-19.47%
TTM Avg
-57.88%
3Y Avg
-52.57%
5Y Avg
-47.02%
Market Cap
$516.76M
Return on Invested Capital (ROIC)
-56.99%
TTM Avg
-66.45%
3Y Avg
-57.50%
5Y Avg
-60.06%
Market Cap
$548.51M
Return on Invested Capital (ROIC)
-23.45%
TTM Avg
-110.35%
3Y Avg
-97.44%
5Y Avg
-86.64%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $529.58M | -26.20% | -62.45% | -73.92% | -58.19% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -317.86% | -177.04% | -169.25% | -196.25% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | -0.81% | -8.59% | -110.96% | -102.03% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -16.89% | -20.74% | -75.97% | -65.59% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -18.20% | -95.31% | -87.63% | -71.60% |
| ProKidney Corp. (PROK)vs › | $538.01M | -78.31% | -49.75% | -41.99% | -101.04% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.47% | -57.88% | -52.57% | -47.02% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -56.99% | -66.45% | -57.50% | -60.06% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | -23.45% | -110.35% | -97.44% | -86.64% |
| 908 Devices Inc. (MASS)vs › | $505.87M | -18.90% | -35.16% | -27.40% | -20.34% |
ROIC
-26.2%
ROE
-24.9%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -26.20% |
| 2026-03-31 | -53.81% |
| 2025-12-31 | -61.34% |
| 2025-09-30 | -60.82% |
| 2025-06-30 | -110.07% |
| 2025-03-31 | -107.24% |
| 2024-12-31 | -98.09% |
| 2024-09-30 | -80.42% |
| 2024-06-30 | -79.72% |
| 2024-03-31 | -68.44% |
| 2023-12-31 | -62.09% |
| 2023-09-30 | -85.30% |
| 2023-06-30 | -67.41% |
| 2023-03-31 | -62.36% |
| 2022-12-31 | -57.29% |
| 2022-09-30 | -33.27% |
| 2022-06-30 | -26.49% |
| 2022-03-31 | -22.47% |
| 2021-12-31 | -16.52% |
| 2021-09-30 | -22.88% |
| 2021-06-30 | -19.69% |
| 2021-03-31 | -13.35% |
| 2020-12-31 | -11.12% |
| 2020-09-30 | -25.35% |
| 2020-06-30 | -20.02% |
| 2019-12-31 | -100.33% |
